CMO & CDMO Biotechnology Market

CMO & CDMO Biotechnology Market

Category : Healthcare & Life Sciences Reports | Delivery Format : PDF,PPT | Publisher: Reports and Insights | Pages : 241

CMO & CDMO Biotechnology Market

To learn more about this report, request a free sample copy

CMO & CDMO Biotechnology Market Overview

The report is titled as ‘CMO & CDMO Biotechnology Market: Opportunity Analysis and Future Assessment 2022-2030’. An overview of conceptual frameworks, analytical approaches of the CMO & CDMO Biotechnology Market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market.

The global CMO & CDMO biotechnology market is expected to reach at a value of US$ 27.5 Bn by 2030 end at a CAGR of 10.8%

CMO & CDMO Biotechnology Introduction

A Contract Manufacturing Organization (CMO) and a Contract Development and Manufacturing Organization (CDMO) refers to an entity or association of people that serves other companies in the pharmaceutical field on a contract basis to offer an extensive range of services, scaling from drug development through drug manufacturing. This enables the leading pharmaceutical companies to outsource those facets of the business, which can aid with scalability or can sanction the major company to aim their attention on drug discovery and drug marketing as an alternative. The only and major difference between a contract development and manufacturing company (CDMO) and a contract manufacturing company (CMO) is development. CMOs are entities that take a pre-formulated drug and are only responsible for manufacturing the drug, whilst CDMOs are associations that carry out both the development and manufacturing of a drug.

In present times, a growing number of consumers are transitioning towards natural and locally sourced products rather than popular brands. Such factors require state-of-the-art technology apart from other resources. Resultantly,  a rapidly growing number of pharmaceutical companies are looking for services of contract manufacturing / contract development and manufacturing organization (CMO/CDMO). Attributing to which, the global CMO and CDMO biotechnology market is projected to rise substantially in the forthcoming years.

CMO & CDMO Biotechnology Market Segmentation

The global CMO & CDMO biotechnology market is segmented on the basis of CDMO type, application, therapeutic area, product, molecule type, platform/ expression system, end user, and region

By CDMO Type

Whole Drug Development and Manufacturing

Active Pharmaceutical Ingredient (API) Manufacturing

Finished Dosage Formulation (FDF) Development and Manufacturing (Injectable)

By Therapeutic Area

Oncology

Infectious Diseases

Neurology

CVS

Metabolic Disorders/Endocrinology

Other Therapeutic Areas

By Product

Monoclonal Antibodies

Antibody Fragments

Recombinant Proteins

Vaccines

Biosimilars

Therapeutic Proteins

Others

By Molecule Type

Viral Vector Manufacturing

Cell and Gene Therapies (CGT)

API manufacturing

Small molecule API manufacturers

Biologics API Manufacturing

Injectable manufacturing

By Application

Preclinical CMO/CDMO

Clinical CMO/CDMO

Commercial CMO/CDMO

Others

By Platform/ Expression System

Mammalian

Microbial

Bacteria

Yeast

Insect

Others

By End User

Pharmaceutical & Biotechnology Companies

Medical Device Companies

Academic Institutes and Research Centers

By Region

North America

Latin America

Europe

Asia Pacific

Middle East

Africa

CMO & CDMO Biotechnology Market Key Players

Some of the key participating players in global CMO & CDMO Biotechnology market are:

Boehringer Ingelheim Group

Wuxi Biologics

Samsung Biologics

Lonza Group

Fujifilm Diosynth Biotechnologies USA Inc.

Toyobo Co. Limited

Parexel International Corporation

Icon PLC

Binex Co. Limited

JRS Pharma

Rentschler Biotechnologies

AGC Biologics

Sandoz Biopharmaceuticals (Novartis AG)

Catalent Inc.

AbbVie Contract Manufacturing

Factors that are benchmarked while estimating the market

Various factors that are benchmarked while estimating the market growth includes (but not restricted to):

New product designs and launches

Current product compliance

Reimbursement

Concerns for use of CMO & CDMO Biotechnology

Advantages of CMO & CDMO Biotechnology

Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decisions.

A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s product sales, previous growth rates and market expansion plans are considered to generate market share in the market.


Summarized Info Details
Base Year: 2021 Forecast Period: 2022-2030
Key Geographies:
  • North America, Europe, Asia Pacific, Latin America, Middle East, & Africa
Market Segmentation:
  • The global CMO & CDMO biotechnology market is segmented on the basis of CDMO type, application, therapeutic area, product, molecule type, platform/ expression system, end user, and region
Key Players:

Some of the key participating players in global CMO & CDMO Biotechnology market are Boehringer Ingelheim Group, Wuxi Biologics, Samsung Biologics, Lonza Group, Fujifilm Diosynth Biotechnologies USA Inc., Toyobo Co. Limited, Parexel International Corporation, Icon PLC, Binex Co. Limited, JRS Pharma, Rentschler Biotechnologies, AGC Biologics, Sandoz Biopharmaceuticals (Novartis AG), Catalent Inc., AbbVie Contract Manufacturing, and among others

Report Coverage:
  • Rapidly growing number of pharmaceutical companies are looking for services of contract manufacturing / contract development and manufacturing organization (CMO/CDMO)
Market Size: US$ 27.5 Bn by 2030 CAGR: 10.8% (2022-2030)

To learn more about this report, request a free sample copy


Select License Type


Frequently Asked Questions

The global CMO & CDMO biotechnology market is expected to reach at a value of US$ 27.5 Bn by 2030 end at a CAGR of 10.8%

Rapidly growing number of pharmaceutical companies are looking for services of contract manufacturing / contract development and manufacturing organization (CMO/CDMO)

The global CMO & CDMO biotechnology market is segmented on the basis of CDMO type, application, therapeutic area, product, molecule type, platform/ expression system, end user, and region

Some of the key participating players in global CMO & CDMO Biotechnology market are Boehringer Ingelheim Group, Wuxi Biologics, Samsung Biologics, Lonza Group, Fujifilm Diosynth Biotechnologies USA Inc., Toyobo Co. Limited, Parexel International Corporation, Icon PLC, Binex Co. Limited, JRS Pharma, Rentschler Biotechnologies, AGC Biologics, Sandoz Biopharmaceuticals (Novartis AG), Catalent Inc., AbbVie Contract Manufacturing, and among others


US
US
1820 Avenue M, Brooklyn, NY 11230, United States
APAC
APAC
315,Shopping Center,Kota-324007,Rajasthan
APAC
APAC
Suite -104, D-20, Sector-63, Noida. Uttar Pradesh - 201014, India

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy

OK